- 05 November
-
Medsintez Plant participated in a key industry event, Product Innovation Fair in Medicine and Healthcare, which took place in Moscow on October 29–30. Viktor Fisenko, First Deputy Minister of Healthcare of Russia, attended the exhibition of domestic innovations in the field of drugs and medical products.
- 25 October
-
The 3d Scientific and Practical Conference The Ural Peaks. Respiratory Infections 2025 was held in Ekaterinburg on October 15–16 as part of the 4th International Forum Days of Virology 2025. The event organized by the Ministry of Health of the Sverdlovsk Region, the Smorodintsev Research Institute of Influenza, and the Ural State Medical University brought together over 1,100 participants in person and online from 36 cities across Russia.
- 24 October
-
In September 2025, the Russian Ministry of Health issued a registration certificate for a new dosage form of the broad-spectrum antiviral drug TRIAZAVIRIN® for the treatment of ARVI in school-age children—100 mg.
- 20 October
-
On October 10, 2025, a representative delegation visited the Medsintez Plant. Among the visitors, there were members of the State Duma of the Russian Federation, representatives of the Government and Legislative Assembly of the Sverdlovsk Region, the head of the Novouralsk Urban District, and leading regional experts in the field of medical science. The main purpose of the visit was to assess the enterprise's success in import-substituting drug production, become familiar with its brand-new products, and discuss development options of the pharmaceutical industry in the region.
- Home
- Cluster members
- Medsintez Plant LLC
Medsintez Plant LLC
Medsintez Plant LLC is a modern full-cycle biotechnological enterprise for development and production of pharmaceutical products complying with the international GMP requirements and ISO standards. The Medsintez Plant has been present on the Russian market for 20 years and is an active participant of drug import substitution programs in the Russian Federation.
The company produces genetically engineered and analogue human insulins Rosinsulin, a veterinary insulin Vinsuvet, a recombinant human follicle-stimulating hormone for the treatment of infertility Primapur, a recombinant human albumin, an innovative antiviral drug Triazavirin, hypoglycemic drugs Liraglutide and Semaglutide, infusion solutions and solutions for automated apheresis, as well as substances produced through chemical and biotechnological synthesis.
Main products of the enterprise are genetically engineered and analogue human insulins Rosinsulin, produced in cartridges, vials and pre-filled injection pens. The enterprise implements fully integrated production of the whole product range of genetically engineered human insulin Rosinsulin and analogue human insulins Rosinsulin Aspart R and Rosinsulin Glargine made of our own APIs. The plant also produces the first Russian veterinary species-specific insulin Vinsuvet, separately for cats and for dogs. In 2023, the Plant launched the production of a full cycle of hypoglycemic drugs for treating type II diabetes mellitus: Liraglutide and Semaglutide.
Triazavirin is a direct-acting antiviral drug developed by Russian scientists based on the original molecule. It is effective for the treatment and prevention of viral diseases, has a wide range of direct antiviral activity against RNA viral infections such as influenza, acute respiratory viral infection, COVID-19. Triazavirin is recommended by the Ministry of Health of the Russian Federation for treatment of influenza and ARVI in adults, and is the only drug approved for both treatment and prevention of COVID-19. Today, the company is developing a complex of antiviral drugs.
Primapur is the first Russian drug of recombinant human follicle-stimulating hormone for human infertility treatment, used in the in vitro fertilization and included in the List of Vital and Essential Drugs. Primapur is available in the form of an easy-to-use disposable injection pen. Today, the company is developing other hormonal drugs, used in a complex of assisted reproductive technologies, such as recombinant human chorionic gonadotropin, Cetrorelix, which will ensure the drug safety in this area in Russia and enable it not to depend on import supplies.
In 2024 the full-cycle production of the world's first registered recombinant human albumin for widespread use in medicine was launched.
One of the major directions for development of the Medsintez Plant is contract manufacturing. Among partners of the enterprise are the largest international pharmaceutical companies such as Bayer, STADA, iVFarma, Promomed, etc.
High-tech Russian production at the Medsintez Plant ensures a high level of quality and safety of manufactured medicines. The company’s products are supplied to all regions of Russia. The production capacity of the plant is enough to cover 100% of the country’s needs for vital insulin medications and drugs for the treatment of infertility, as well as to provide major support to the country during epidemics and pandemics of viral infections.
15, Torgovaya St., Novouralsk, Sverdlovsk Region, Russia
Тel.: +7 (34370) 2-50-61
e-mail: medsintez@mail.ru
.jpg)
